Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

Arce75 Jun. 17 at 5:57 PM

$GUTS Can we expect anything from the 85th ADA Scientific Sessions? This keeps dropping..

0 · Reply

PLATINUM_TRADES Jun. 16 at 2:01 PM

$GUTS $1.98 major support I'll take some here and lower my avg.... $2.50 should be easy for a good day imo🚨🚨

1 · Reply

Invader55 Jun. 13 at 3:08 PM

$GUTS absolute garbage especially if biobitch keeps harping this as a winner. LMAO

0 · Reply

BigSqueezeComing Jun. 13 at 12:18 PM

$GUTS Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions By

1 · Reply

Thestocktraderhubzee Jun. 13 at 11:10 AM

$GUTS Fractyl Health To Present Poster Of New Preclinical Data From Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform At ADA 85th Scientific Sessions

0 · Reply

theflynews Jun. 12 at 4:01 PM

Biotech Alert: Searches spiking for these stocks today - $GUTS - https://thefly.com/permalinks/entry.php/GUTSid4145056?1749743563C38

0 · Reply

BioRich Jun. 12 at 3:06 PM

$GUTS Didn't see this show up on the Fractyl (GUTS) page so re-posting. We're onto something big here folks. Stay above the noise. NO ONE is doing what we're doing. NO ONE. "Innovative Weight Management Solution Drives Buy Rating for Fractyl Health" Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital

0 · Reply

BioRich Jun. 12 at 3:02 PM

$XBI $GUTS PT UPDATE - $12!!! In a recent Tipranks article, "Innovative Weight Management Solution Drives Buy Rating for Fractyl Health", Canaccord Genuity 5-Star analyst Whitney Ijem reiterated a Buy rating on Fractyl Health with a $12 PT. "Whitney Ijem has given his Buy rating due to a combination of factors surrounding Fractyl Health, Inc.’s innovative approach and promising market potential. The company’s Revita medical device platform is positioned as a pioneering solution in the substantial weight maintenance market, addressing a critical need that traditional methods like bypass surgery have not fully resolved. The Revita platform targets the duodenal lining, which plays a crucial role in nutrient sensing and communication with the brain, offering a novel approach to weight management and blood sugar control." Full article: https://www.tipranks.com/news/ratings/innovative-weight-management-solution-drives-buy-rating-for-fractyl-health-ratings Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. Let's make some money. Cheers! ~BioRich Capital $IBB

0 · Reply

BioRich Jun. 11 at 8:22 PM

$ALT Love when ALT Nation tries to dog competitors like $GUTS that are whooping ALT's arse. Enjoy @thaines1. Here's the 3-month. Keep pumping ALT though. I want more money to buy more $GUTS, a real company. Or $GPCR. Or $VKTX. Or $VERU. Rainy, in case you can't see it, $GUTS is up 88.38% over the past 3 months. You're welcome. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital

3 · Reply

thaines1 Jun. 11 at 7:58 PM

$ALT Coming from the guy who’s married to Stocktwits and who’s relationship with $GUTS Looks about as successful as the relationship between Johnny Depp and Amber Heard. About as costly too 😂

1 · Reply

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 13 days ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 4 weeks ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 4 weeks ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 4 weeks ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 4 weeks ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 4 weeks ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 6 weeks ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 7 weeks ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 3 months ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 3 months ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 4 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 4 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 6 months ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 6 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 7 months ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 7 months ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 7 months ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 8 months ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 8 months ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 8 months ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 9 months ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 10 months ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 10 months ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 10 months ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 7, 2024, 7:00 AM EDT - 11 months ago

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

Jul 30, 2024, 7:00 AM EDT - 11 months ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

Jun 23, 2024, 1:30 PM EDT - 1 year ago

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's

May 20, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

May 13, 2024, 10:37 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:00 PM EDT - 1 year ago

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

May 8, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

May 7, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

Apr 30, 2024, 8:38 AM EDT - 1 year ago

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 1, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Mar 19, 2024, 8:08 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

IVP OM PACB

Mar 12, 2024, 2:06 PM EDT - 1 year ago

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Mar 12, 2024, 8:38 AM EDT - 1 year ago

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Feb 20, 2024, 8:38 AM EST - 1 year ago

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Feb 4, 2024, 6:16 AM EST - 1 year ago

U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings

AS AHR AMDI ANRO FBLG FLUT KYTX

Feb 2, 2024, 1:44 PM EST - 1 year ago

Fractyl Health valued at $654.6 mln in tepid debut

Feb 1, 2024, 9:39 PM EST - 1 year ago

Fractyl Health prices US IPO below range to raise $110 mln

Feb 1, 2024, 8:08 PM EST - 1 year ago

Fractyl Health Announces Pricing of Initial Public Offering

Dec 17, 2023, 4:47 AM EST - 1 year ago

Fractyl Health Aims For $100 Million IPO Raise

Arce75 Jun. 17 at 5:57 PM

$GUTS Can we expect anything from the 85th ADA Scientific Sessions? This keeps dropping..

0 · Reply

PLATINUM_TRADES Jun. 16 at 2:01 PM

$GUTS $1.98 major support I'll take some here and lower my avg.... $2.50 should be easy for a good day imo🚨🚨

1 · Reply

Invader55 Jun. 13 at 3:08 PM

$GUTS absolute garbage especially if biobitch keeps harping this as a winner. LMAO

0 · Reply

BigSqueezeComing Jun. 13 at 12:18 PM

$GUTS Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions By

1 · Reply

Thestocktraderhubzee Jun. 13 at 11:10 AM

$GUTS Fractyl Health To Present Poster Of New Preclinical Data From Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform At ADA 85th Scientific Sessions

0 · Reply

theflynews Jun. 12 at 4:01 PM

Biotech Alert: Searches spiking for these stocks today - $GUTS - https://thefly.com/permalinks/entry.php/GUTSid4145056?1749743563C38

0 · Reply

BioRich Jun. 12 at 3:06 PM

0 · Reply

BioRich Jun. 12 at 3:02 PM

0 · Reply

BioRich Jun. 11 at 8:22 PM

3 · Reply

thaines1 Jun. 11 at 7:58 PM

$ALT Coming from the guy who’s married to Stocktwits and who’s relationship with $GUTS Looks about as successful as the relationship between Johnny Depp and Amber Heard. About as costly too 😂

1 · Reply

PLATINUM_TRADES Jun. 11 at 4:58 PM

$GUTS I'll see u at $3.00! 🚨🚨

3 · Reply

theflynews Jun. 11 at 4:41 PM

Biotech Alert: Searches spiking for these stocks today - $GUTS - https://thefly.com/permalinks/entry.php/GUTSid4144343?1749660012C38

0 · Reply

BioRich Jun. 11 at 3:03 PM

$XBI Great callout on $GUTS being Peter Thiel backed. And for good reason. Fractyl ($GUTS) is addressing the Holy Grail of weight loss...weight loss retention following GLP-1 discontinuation. NO ONE is doing this, which makes them a perfect Buyout or Partnership target for ANY Bio working with GLP-1s. Obvious suitors would be $NVO or $LLY but can see PFE join the equation if/when they acquire $VKTX. Overall exciting times! Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers!

0 · Reply